SanDiego, CA, – Solulink, Inc., an emerging life science tools company with expertise in biomolecularlinking,today announced the completion of a new round of equity financing. The funds will enable Solulink to accelerate the commercialization ofitsHybriLink ‘any antibody in any color’ labeling technology. TheHybriLink technology satisfiesflow cytometrists’ unmet needs and enables antibody suppliersto addressmarket demand for greaterflow cytometrymultiplexing ease and convenience.

TheHybriLink technology solvesthe ‘missing color’ problem:the inability to find the needed antibody labeled with the rightfluorophore (color). Often,the desired combination is not commercially available.

By providing a simple way tomix andmatch any fluorophore with any antibody on demand, just?in?time atthe point?of?use,HybriLink dramatically streamlinesthe development and expansion ofmulticolor flow panelsforflow cytometry research labs. Solulink believesthatHybriLink’s ability to offer all antibodiesin allfluorophores – including the next generation of emerging fluorophores – resolves a fundamental challenge in flow cytometry and will expand the overallflow cytometry reagentsmarket size.

“With theHybriLink technology, antibodies are labeled with a tag and the fluorophoreslabeled with a complimentary tag. These two components are then combined to formthe labeled antibody,ready to use with nearly 100% efficiency. Labeled?antibody providers can now supply tagged antibodies and complimentary tagged fluorophores, which allow the userto create an unlimited number of labeled antibodies,” said Solulink’s CEO,David McCarty.

“Solulink’sHybriLink technology simultaneously fulfillstwo increasingly critical needsin flow cytometry: HybriLink offersflow cytometrists an easy way to create, or optimize,multi?colorflow panels on demand by labeling any antibody with any color, without chemistry or chromatography. In addition, HybriLink offersstrategic partners a radically simplified way to introduce new fluorophoresinto their library oflabeled antibodies, while expanding theirmarket potential.”

The company is currently providing early accesstoHybriLink productsto select customers. Attractive licensing terms are available forlicensees and commercial partnersin the flow cytometry and antibody reagentsmarkets.“Flow cytometry instruments and fluorophores have advanced rapidly; however, antibody?labeling technology hasstagnated and the few advances have notmet user ormarket expectations,” added MarkHorne, CEO, Plymouth Ventures. “Based on our diligence results, we are confidentthatthe HybriLink technology represents amajor advancementforflow cytometry and will be embraced by the

research community.”

About Solulink

Solulink, a privately?held life science tools company, develops,manufactures andmarkets proprietary, next generation linking technology forthe development and improvement of productsin the research assay and diagnosticmarkets. Solulink’slatestinnovation,theHybriLink Technology, improvesthe capabilities of end users, developers and suppliersto utilize the growing wide variety of detection technologiesforresearch and diagnostic life science assays. Solulinkmarketstheir products directly and through distributors and licensing partners world?wide.